PD-L1 predicts chemotherapy resistance in large-cell neuroendocrine carcinoma

Che, Yun; Luo, Zhiwen; Cao, Yanan; Sun, Nan; Xue, Qi; He, Jie

doi:10.1093/bjs/znac335

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large cell neuroendocrined carcinoma (LCNEC) is a rare and aggressive tumor with a short median survival time mostly because of limited effective therapies. 1 Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm of several solid tumors, to date, studies on ICI treatment in LCNEC are nascent. 2 , 3 …”

Section: Introductionmentioning

confidence: 99%

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report

Zhang,

Yang,

Shao

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.

show abstract

Section: Introductionmentioning

confidence: 99%